NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · IEX Real-Time Price · USD
2.170
-0.035 (-1.59%)
Apr 19, 2024, 3:59 PM EDT - Market closed
Company Description
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels.
Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019.
The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
NEXGEL, Inc.
| Country | United States |
| Founded | 1997 |
| IPO Date | Dec 22, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Adam R. Levy |
Contact Details
Address: 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 United States | |
| Phone | 215 702-8550 |
| Website | nexgel.com |
Stock Details
| Ticker Symbol | NXGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.50 |
| CIK Code | 0001468929 |
| CUSIP Number | 65344E107 |
| ISIN Number | US65344E1073 |
| Employer ID | 26-4042544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Adam R. Levy | Chief Executive Officer, President and Director |
| Adam E. Drapczuk III | Chief Financial Officer |
| Gregory Robb | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 10-K | Annual Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 424B5 | Filing |
| Feb 21, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |